Literature DB >> 7608697

Dose standardisation of botulinum toxin.

M H Marion, M Sheehy, S Sangla, S Soulayrol.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7608697      PMCID： PMC1073616          DOI： 10.1136/jnnp.59.1.102

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Dose standardisation of botulinum toxin.

Authors:  E J Schantz; E A Johnson
Journal:  Lancet       Date:  1990-02-17       Impact factor: 79.321

2.  Dose standardisation of botulinum toxin.

Authors:  N Quinn; M Hallett
Journal:  Lancet       Date:  1989-04-29       Impact factor: 79.321

3.  Potency equivalence of botulinum toxin preparations.

Authors:  P Hambleton; A M Pickett
Journal:  J R Soc Med       Date:  1994-11       Impact factor: 5.344

4.  Dose standardisation of botulinum toxin.

Authors:  A M Pickett; P Hambleton
Journal:  Lancet       Date:  1994-08-13       Impact factor: 79.321

5.  Botulinum toxin: dangerous terminology errors.

Authors:  M F Brin; A Blitzer
Journal:  J R Soc Med       Date:  1993-08       Impact factor: 5.344
  5 in total
  18 in total

1.  Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

Authors:  D Ranoux; C Gury; J Fondarai; J L Mas; M Zuber
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

2.  Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay.

Authors:  Dirk Dressler; Gerd Mander; Klaus Fink
Journal:  J Neural Transm (Vienna)       Date:  2011-10-05       Impact factor: 3.575

3.  Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay.

Authors:  Dirk Dressler; Lizhen Pan; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2018-06-26       Impact factor: 3.575

4.  Use of Botulinum Toxin in Ophthalmology.

Authors:  Michael J Wan; Sara AlShaker; David G Hunter
Journal:  Handb Exp Pharmacol       Date:  2021

5.  Clinical Pharmacology of Botulinum Toxin Drugs.

Authors:  Dirk Dressler
Journal:  Handb Exp Pharmacol       Date:  2021

Review 6.  Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.

Authors:  A Ferrari; M Manca; V Tugnoli; L Alberto
Journal:  Funct Neurol       Date:  2018 Jan/Mar

7.  Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay.

Authors:  Lizhen Pan; Hans Bigalke; Bruno Kopp; Lingjing Jin; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2019-11-09       Impact factor: 3.575

8.  Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.

Authors:  Z Nüssgens; P Roggenkämper
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-04       Impact factor: 3.117

9.  Botulinum toxin.

Authors:  P K Nigam; Anjana Nigam
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

10.  Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity.

Authors:  Kerstin Müller; Eilhard Mix; Fereshte Adib Saberi; Dirk Dressler; Reiner Benecke
Journal:  J Neural Transm (Vienna)       Date:  2009-04-08       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.